Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment.

ABSTRACT:

Introduction

The safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia using apolipoprotein E (APOE) genotyping is unknown.

Methods

We randomized 114 individuals with MCI to receive estimates of 3-year risk of conversion to AD dementia informed by APOE genotyping (disclosure arm) or not (non-disclosure arm) in a non-inferiority clinical trial. Primary outcomes were anxiety and depression scores. Secondary outcomes included other psychological measures.

Results

Upper confidence limits for randomization arm differences were 2.3 on the State Trait Anxiety Index and 0.5 on the Geriatric Depression Scale, below non-inferiority margins of 3.3 and 1.0. Moreover, mean scores were lower in the disclosure arm tha

SUBMITTER: Christensen KD 

PROVIDER: S-EPMC7087414 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature